{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:26:24Z","timestamp":1789129584746,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54MD007582, U54CA233396-01 and 5P20CA192990-04"],"award-info":[{"award-number":["U54MD007582, U54CA233396-01 and 5P20CA192990-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>5-Fluorouracil (5-FU) is a standard treatment option for colorectal cancer (CRC) but its rapid metabolism and systemic instability (short half-life) has hindered its therapeutic efficacy. The objective of this study was to develop a novel drug delivery system, solid lipid nanoparticle (SLN), capable of delivering high payload of 5-FU to treat CRC. The rational was to improve 5FU-nanocarrier compatibility and therapeutic efficacy. The SLN-loaded 5-FU was developed by utilizing a Strategic and unique Method to Advance and Refine the Treatment (SMART) of CRC through hot and cold homogenization approach. The SLN was made of unique PEGylated lipids and combination of the surfactants. Cytotoxicity studies, clonogenic assay, flow cytometry and confocal imaging were conducted to evaluate the effectiveness and cellular uptake of 5FU-SLN<jats:sub>4<\/jats:sub> in HCT-116 cancer cells. Pharmacokinetic (PK) parameters and receptor expressions were determined while tumor efficacy studies were conducted on mouse bearing subcutaneous HCT-116 cancer. Among the all the formulations, 5FU-SLN<jats:sub>4<\/jats:sub> was the most effective with particle size of was 263\u2009\u00b1\u20093\u00a0nm, zeta potential was 0.1\u2009\u00b1\u20090.02 and entrapment efficiency of 81\u2009\u00b1\u200910%. The IC<jats:sub>50<\/jats:sub> value of 5FU-SLN<jats:sub>4<\/jats:sub> (7.4\u2009\u00b1\u20090.02\u00a0\u00b5M) was 2.3 fold low compared with 5-FU (17.7\u2009\u00b1\u20090.03\u00a0\u00b5M). For tumor efficacy studies, 5FU-SLN<jats:sub>4<\/jats:sub> significantly inhibited tumor growth in comparison to 5-FU while area-under plasma concentration-time curve (AUC) of 5FU-SLN<jats:sub>4<\/jats:sub> was 3.6 fold high compared with 5-FU. HER2 receptors expression were markedly reduced in 5-FU-SLN<jats:sub>4<\/jats:sub> treated mice compared with 5FU and liver and kidney tissues showed no toxicity at dose of 20\u00a0mg\/kg. 5FU-SLN<jats:sub>4<\/jats:sub> was highly cytotoxic against HCT-116 cells and significantly inhibited subcutaneous tumor growth in mice compared with 5-FU. This emphasizes the significance of developing a smart nano-delivery system to optimize the delivery efficiency of anticancer drugs to tumors.<\/jats:p>","DOI":"10.1038\/s41598-020-73218-6","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T10:02:42Z","timestamp":1602496962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Taylor","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Affram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony L.","family":"Nottingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Amissah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Trevino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Agyare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"73218_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334. https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"73218_CR2","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.32346","volume":"125","author":"CA Doubeni","year":"2019","unstructured":"Doubeni, C. A. Early-onset colorectal cancer: what reported statistics can and cannot tell us and their implications. Cancer 125, 3706\u20133708. https:\/\/doi.org\/10.1002\/cncr.32346 (2019).","journal-title":"Cancer"},{"key":"73218_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3748\/wjg.v22.i2.582","volume":"22","author":"A Gulbake","year":"2016","unstructured":"Gulbake, A., Jain, A., Jain, A., Jain, A. & Jain, S. K. Insight to drug delivery aspects for colorectal cancer. World J. Gastroenterol. 22, 582\u2013599. https:\/\/doi.org\/10.3748\/wjg.v22.i2.582 (2016).","journal-title":"World J. Gastroenterol."},{"key":"73218_CR4","unstructured":"Richarlm. Colorectal Cancer Awareness Month (2019). https:\/\/yourhealthradio.org\/2019\/03\/20\/colorectalcancer-awareness-month\/. Accessed 18 June 2019."},{"key":"73218_CR5","first-page":"245","volume":"2","author":"O Udofot","year":"2015","unstructured":"Udofot, O. Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines. Integr. Cancer Sci. Ther. 2, 245 (2015).","journal-title":"Integr. Cancer Sci. Ther."},{"key":"73218_CR6","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1038\/s41598-017-09859-x","volume":"7","author":"P Gokare","year":"2017","unstructured":"Gokare, P. et al. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Sci. Rep. 7, 9711. https:\/\/doi.org\/10.1038\/s41598-017-09859-x (2017).","journal-title":"Sci. Rep."},{"key":"73218_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1188\/14.CJON.581-585","volume":"18","author":"J Latchman","year":"2014","unstructured":"Latchman, J., Guastella, A. & Tofthagen, C. 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice. Clin. J. Oncol. Nurs. 18, 581\u2013585. https:\/\/doi.org\/10.1188\/14.CJON.581-585 (2014).","journal-title":"Clin. J. Oncol. Nurs."},{"key":"73218_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/nano9040638","volume":"9","author":"B Garcia-Pinel","year":"2019","unstructured":"Garcia-Pinel, B. et al. Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials (Basel) 9, 2. https:\/\/doi.org\/10.3390\/nano9040638 (2019).","journal-title":"Nanomaterials (Basel)"},{"key":"73218_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.colsurfb.2010.12.024","volume":"84","author":"FAC Carla Vitorino","year":"2011","unstructured":"Carla Vitorino, F. A. C., Almeida, A. J., Sousa, J. J. & Pais, A. A. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf. B Biointerfaces 84, 117\u2013130 (2011).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"73218_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.dib.2015.11.038","volume":"6","author":"D Pooja","year":"2016","unstructured":"Pooja, D., Tunki, L., Kulhari, H., Reddy, B. B. & Sistla, R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief 6, 15\u201319 (2016).","journal-title":"Data Brief"},{"key":"73218_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.addr.2007.04.008","volume":"59","author":"HL Wong","year":"2007","unstructured":"Wong, H. L., Bendayan, R., Rauth, A. M., Li, Y. & Wu, X. Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59, 491\u2013504 (2007).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"73218_CR12","doi-asserted-by":"crossref","unstructured":"Daly, M. C. & Paquette, I. M. Surveillance, epidemiology, and end results (SEER) and SEER-medicare databases: Use in clinical research for improving colorectal cancer outcomes. Clin. Colon Rectal Surg. 32, 61\u201368 (2019).","DOI":"10.1055\/s-0038-1673355"},{"key":"73218_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.colsurfb.2014.07.024","volume":"122","author":"N Ashwanikumar","year":"2014","unstructured":"Ashwanikumar, N., Kumar, N. A., Asha Nair, S. & Vinod Kumar, G. S. Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicity. Colloids Surf. B Biointerfaces 122, 520\u2013528 (2014).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"73218_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.canlet.2014.10.029","volume":"356","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett. 356, 781\u2013790 (2015).","journal-title":"Cancer Lett."},{"key":"73218_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcrpr.2017.02.002","volume":"4","author":"SP Chandran","year":"2017","unstructured":"Chandran, S. P., Natarajan, S. B., Chandraseharan, S. & Shahimi, M. S. B. M. Nano drug delivery strategy of 5-fluorouracil for the treatment ofcolorectal cancer. J. Cancer Res. Pract. 4, 45\u201348 (2017).","journal-title":"J. Cancer Res. Pract."},{"key":"73218_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","volume":"6","author":"P Ganesan","year":"2017","unstructured":"Ganesan, P. & Narayanasamy, D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain. Chem. Pharm. 6, 37\u201356 (2017).","journal-title":"Sustain. Chem. Pharm."},{"key":"73218_CR17","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.msec.2013.01.037","volume":"33","author":"JKR Sacheen Kumar","year":"2013","unstructured":"Sacheen Kumar, J. K. R. High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater. Sci. Eng. 33, 1842\u20131852 (2013).","journal-title":"Mater. Sci. Eng."},{"key":"73218_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.colsurfa.2016.06.034","volume":"510","author":"GD Kalaycioglu","year":"2016","unstructured":"Kalaycioglu, G. D. & Aydogan, N. Preparation and investigation of solid lipid nanoparticles for drugdelivery. Colloids Surf. A Physicochem. Eng. Asp. 510, 77\u201386 (2016).","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"73218_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.04.044","volume":"453","author":"J Siepmann","year":"2013","unstructured":"Siepmann, J. & Siepmann, F. Mathematical modeling of drug dissolution. Int. J. Pharm. 453, 12\u201324. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.04.044 (2013).","journal-title":"Int. J. Pharm."},{"key":"73218_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","volume":"418","author":"J Siepmann","year":"2011","unstructured":"Siepmann, J. & Peppas, N. A. Higuchi equation: derivation, applications, use and misuse. Int. J. Pharm. 418, 6\u201312 (2011).","journal-title":"Int. J. Pharm."},{"key":"73218_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/annonc\/mdi282","volume":"16","author":"A Italiano","year":"2005","unstructured":"Italiano, A. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann. Oncol. 16, 1503\u20131507 (2005).","journal-title":"Ann. Oncol."},{"key":"73218_CR22","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B. et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228\u20133237. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3747 (2012).","journal-title":"Cancer Res."},{"key":"73218_CR23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/cancers6020926","volume":"6","author":"A Xiong","year":"2014","unstructured":"Xiong, A., Yang, Z., Shen, Y., Zhou, J. & Shen, Q. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers 6, 926\u2013957 (2014).","journal-title":"Cancers"},{"key":"73218_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7150\/ijbs.5.466","volume":"5","author":"HI El-Sayyad","year":"2009","unstructured":"El-Sayyad, H. I. et al. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int. J. Biol. Sci. 5, 466\u2013473. https:\/\/doi.org\/10.7150\/ijbs.5.466 (2009).","journal-title":"Int. J. Biol. Sci."},{"key":"73218_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3904\/kjim.2006.21.1.43","volume":"21","author":"JH Baek","year":"2006","unstructured":"Baek, J. H. et al. Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. Korean J. Intern. Med. 21, 43\u201345. https:\/\/doi.org\/10.3904\/kjim.2006.21.1.43 (2006).","journal-title":"Korean J. Intern. Med."},{"key":"73218_CR26","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"Meta-Analysis Group In, C","year":"1998","unstructured":"Meta-Analysis Group In, C et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 16, 3537\u20133541. https:\/\/doi.org\/10.1200\/JCO.1998.16.11.3537 (1998).","journal-title":"J. Clin. Oncol."},{"key":"73218_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/bf02994764","volume":"26","author":"BT Yu","year":"2003","unstructured":"Yu, B. T., Sun, X. & Zhang, Z. R. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch. Pharm. Res. 26, 1096\u20131101. https:\/\/doi.org\/10.1007\/bf02994764 (2003).","journal-title":"Arch. Pharm. Res."},{"key":"73218_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2407-8-103","volume":"8","author":"S Li","year":"2008","unstructured":"Li, S., Wang, A., Jiang, W. & Guan, Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer 8, 103. https:\/\/doi.org\/10.1186\/1471-2407-8-103 (2008).","journal-title":"BMC Cancer"},{"key":"73218_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/10837450903246390","volume":"15","author":"B Du","year":"2010","unstructured":"Du, B., Yan, Y., Li, Y., Wang, S. & Zhang, Z. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. Pharm. Dev. Technol. 15, 346\u2013353. https:\/\/doi.org\/10.3109\/10837450903246390 (2010).","journal-title":"Pharm. Dev. Technol."},{"key":"73218_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0284185113475923","volume":"54","author":"SJ Choi","year":"2013","unstructured":"Choi, S. J., Kim, H. S., Ahn, S. J., Jeong, Y. M. & Choi, H. Y. Evaluation of the growth pattern of carcinoma of colon and rectum by MDCT. Acta Radiol. 54, 487\u2013492. https:\/\/doi.org\/10.1177\/0284185113475923 (2013).","journal-title":"Acta Radiol."},{"issue":"Suppl 3","key":"73218_CR31","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1752-0509-8-S3-S2","volume":"8","author":"S Sun","year":"2014","unstructured":"Sun, S., Klebaner, F. & Tian, T. A new model of time scheme for progression of colorectal cancer. BMC Syst. Biol. 8(Suppl 3), S2. https:\/\/doi.org\/10.1186\/1752-0509-8-S3-S2 (2014).","journal-title":"BMC Syst. Biol."},{"key":"73218_CR32","first-page":"2128","volume":"45","author":"DM Ota","year":"1985","unstructured":"Ota, D. M. & Drewinko, B. Growth kinetics of human colorectal carcinoma. Cancer Res. 45, 2128\u20132131 (1985).","journal-title":"Cancer Res."},{"key":"73218_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3791\/484","volume":"10","author":"W Tseng","year":"2007","unstructured":"Tseng, W., Leong, X. & Engleman, E. Orthotopic mouse model of colorectal cancer. J. Vis. Exp. 10, 484. https:\/\/doi.org\/10.3791\/484 (2007).","journal-title":"J. Vis. Exp."},{"key":"73218_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","volume":"29","author":"S Siena","year":"2018","unstructured":"Siena, S. et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 29, 1108\u20131119. https:\/\/doi.org\/10.1093\/annonc\/mdy100 (2018).","journal-title":"Ann. Oncol."},{"key":"73218_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4251\/wjgo.v11.i4.335","volume":"11","author":"XY Wang","year":"2019","unstructured":"Wang, X. Y. et al. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J. Gastrointest. Oncol. 11, 335\u2013347. https:\/\/doi.org\/10.4251\/wjgo.v11.i4.335 (2019).","journal-title":"World J. Gastrointest. Oncol."},{"key":"73218_CR36","doi-asserted-by":"publisher","first-page":"1290741","DOI":"10.1080\/19932820.2017.1290741","volume":"12","author":"R Bendardaf","year":"2017","unstructured":"Bendardaf, R., El-Serafi, A., Syrjanen, K., Collan, Y. & Pyrhonen, S. The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients. Libyan J. Med. 12, 1290741. https:\/\/doi.org\/10.1080\/19932820.2017.1290741 (2017).","journal-title":"Libyan J. Med."},{"key":"73218_CR37","doi-asserted-by":"publisher","first-page":"e0128159","DOI":"10.1371\/journal.pone.0128159","volume":"10","author":"SN Steinway","year":"2015","unstructured":"Steinway, S. N., Dang, H., You, H., Rountree, C. B. & Ding, W. The EGFR\/ErbB3 pathway acts as a compensatory survival mechanism upon c-Met inhibition in human c-Met+ hepatocellular carcinoma. PLoS ONE 10, e0128159. https:\/\/doi.org\/10.1371\/journal.pone.0128159 (2015).","journal-title":"PLoS ONE"},{"key":"73218_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","volume":"6","author":"DN Poovi Ganesana","year":"2017","unstructured":"Poovi Ganesana, D. N. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain. Chem. Pharm. 6, 37\u201356 (2017).","journal-title":"Sustain. Chem. Pharm."},{"key":"73218_CR39","first-page":"480","volume":"20","author":"RH Muller","year":"1993","unstructured":"Muller, R. H., Schwarz, C., Mehnert, W. & Lucks, J. S. Production of solid lipid nanoparticles (SLN) for controlled drug delivery. Proc. Int. Symp. Control Release Bioact. Mater. 20, 480 (1993).","journal-title":"Proc. Int. Symp. Control Release Bioact. Mater."},{"key":"73218_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","volume":"29","author":"J Ciccolini","year":"2004","unstructured":"Ciccolini, J. et al. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J. Clin. Pharm. Ther. 29, 307\u2013315. https:\/\/doi.org\/10.1111\/j.1365-2710.2004.00569.x (2004).","journal-title":"J. Clin. Pharm. Ther."},{"key":"73218_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/nano8020075","volume":"8","author":"KC Zatta","year":"2018","unstructured":"Zatta, K. C. et al. An inhalable powder formulation based on micro- and nanoparticles containing 5-fluorouracil for the treatment of metastatic melanoma. Nanomaterials Basel 8, 75. https:\/\/doi.org\/10.3390\/nano8020075 (2018).","journal-title":"Nanomaterials Basel"},{"key":"73218_CR42","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1080\/10826076.2011.583372","volume":"34","author":"N Wang","year":"2011","unstructured":"Wang, N., Wang, T., Wang, M., Hao, A. & Li, T. Using ultrafiltration to facilitate simultaneous quantification of 5-fluorouracil in mouse plasma and tissues by HPLC. J. Liq. Chromatogr. Relat. Technol. 34, 2033\u20132047 (2011).","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"73218_CR43","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1208\/s12249-014-0168-x","volume":"15","author":"MN Patel","year":"2014","unstructured":"Patel, M. N. et al. Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique. AAPS PharmSciTech 15, 1498\u20131508. https:\/\/doi.org\/10.1208\/s12249-014-0168-x (2014).","journal-title":"AAPS PharmSciTech"},{"key":"73218_CR44","first-page":"217","volume":"67","author":"S Dash","year":"2010","unstructured":"Dash, S., Murthy, P. N., Nath, L. & Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol. Pharm. Drug Res. 67, 217\u2013223 (2010).","journal-title":"Acta Pol. Pharm. Drug Res."},{"key":"73218_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.15761\/icst.1000150","volume":"2","author":"O Udofot","year":"2015","unstructured":"Udofot, O., Affram, K., Israel, B. & Agyare, E. Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines. Integr. Cancer Sci. Ther. 2, 245\u2013252. https:\/\/doi.org\/10.15761\/icst.1000150 (2015).","journal-title":"Integr. Cancer Sci. Ther."},{"key":"73218_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2009.34","volume":"4","author":"JJ Moser","year":"2009","unstructured":"Moser, J. J., Chan, E. K. & Fritzler, M. J. Optimization of immunoprecipitation-western blot analysis in detecting GW182-associated components of GW\/P bodies. Nat. Protoc. 4, 674\u2013685. https:\/\/doi.org\/10.1038\/nprot.2009.34 (2009).","journal-title":"Nat. Protoc."},{"key":"73218_CR47","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.18632\/oncotarget.27062","volume":"10","author":"O Ayinde","year":"2019","unstructured":"Ayinde, O., Wang, Z., Pinton, G., Moro, L. & Griffin, M. Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition. Oncotarget 10, 4556\u20134569. https:\/\/doi.org\/10.18632\/oncotarget.27062 (2019).","journal-title":"Oncotarget"},{"key":"73218_CR48","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.7314\/apjcp.2015.16.5.2061","volume":"16","author":"GW Hao","year":"2015","unstructured":"Hao, G. W. et al. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac. J. Cancer Prev. 16, 2061\u20132068. https:\/\/doi.org\/10.7314\/apjcp.2015.16.5.2061 (2015).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"73218_CR49","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/bies.201500032","volume":"37","author":"RE McIntyre","year":"2015","unstructured":"McIntyre, R. E., Buczacki, S. J., Arends, M. J. & Adams, D. J. Mouse models of colorectal cancer as preclinical models. BioEssays 37, 909\u2013920. https:\/\/doi.org\/10.1002\/bies.201500032 (2015).","journal-title":"BioEssays"},{"key":"73218_CR50","doi-asserted-by":"publisher","first-page":"e62349","DOI":"10.1371\/journal.pone.0062349","volume":"8","author":"JI Hare","year":"2013","unstructured":"Hare, J. I. et al. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C) and 5-fluorouracil. PLoS ONE 8, e62349. https:\/\/doi.org\/10.1371\/journal.pone.0062349 (2013).","journal-title":"PLoS ONE"},{"key":"73218_CR51","first-page":"e171","volume":"2","author":"O Udofot","year":"2016","unstructured":"Udofot, O. et al. Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. J. Nat. Sci. 2, e171 (2016).","journal-title":"J. Nat. Sci."},{"key":"73218_CR52","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.15.4511","volume":"15","author":"J Harder","year":"2009","unstructured":"Harder, J. et al. EGFR and HER2 expression in advanced biliary tract cancer. World J. Gastroenterol. 15, 4511\u20134517. https:\/\/doi.org\/10.3748\/wjg.15.4511 (2009).","journal-title":"World J. Gastroenterol."},{"key":"73218_CR53","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2407-10-631","volume":"10","author":"Y Pignochino","year":"2010","unstructured":"Pignochino, Y. et al. Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10, 631. https:\/\/doi.org\/10.1186\/1471-2407-10-631 (2010).","journal-title":"BMC Cancer"},{"key":"73218_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10637-012-9891-x","volume":"31","author":"N Walsh","year":"2013","unstructured":"Walsh, N. et al. EGFR and HER2 inhibition in pancreatic cancer. Invest. New Drugs 31, 558\u2013566. https:\/\/doi.org\/10.1007\/s10637-012-9891-x (2013).","journal-title":"Invest. New Drugs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73218-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:49:41Z","timestamp":1670359781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73218-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73218"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73218-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16989"}}